Back

Novel SPECT/CT biomarker in transthyretin cardiac amyloidosis: correlation with myocardial amyloid load and cardiac structure and function

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: New imaging insights into cardiomyopathies Imaging of Myocardial Disease ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Rene Rettl

Medical University of Vienna, Vienna (Austria)

6 More presentations in this session

Presentation thumbnail
Phenotype-genotype discordance in patients with hypertrophic cardiomyopathy: clinical and echocardiographic correlates
Doctor M. SOH (Suwon, KR)
Abstract Slides Video
Presentation thumbnail
Artificial intelligence-driven echocardiographic classification identifies Brugada Syndrome patients at higher arrhythmic risk
Doctor D. Kukavica (Pavia, IT)
Abstract Slides Video
Presentation thumbnail
Echocardiographic deformation imaging as a substitute for cardiac magnetic resonance imaging in arrhythmogenic right ventricular cardiomyopathy risk prediction
Mr F. Kirkels (Utrecht, NL)
Abstract Slides Video
Presentation thumbnail
Estimated population prevalence of cardiac transthyretin amyloidosis as an incidental finding on bone scintigraphy in a university hospital in Colombia
Doctor R. Isaac de Medeiros (Bogota, CO)
Abstract Slides Video
Presentation thumbnail
Prediction of genetic cardiomyopathy by whole exome sequencing and myocardial strain in patients with concentric left ventricle hypertrophy
Doctor M. SOH (Suwon, KR)
Abstract Slides Video

Access the full session

Session thumbnail
New imaging insights into cardiomyopathies

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
What is the best imaging method to assess myocardial viability? 
thumbnail
Congress Presentation
Toxic for the whole heart: from inflammation to radiation
thumbnail
Congress Presentation
Imaging inflammation in acute and chronic pericarditis and response to therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources